Abstract Body (Do not enter title and authors here): Introduction: Structural valve degeneration (SVD) of bioprosthetic tricuspid valves within six months of implantation is exceedingly rare and presents significant management challenges. We describe the diagnostic evaluation and successful transcatheter tricuspid valve-in-valve (ViV) implantation for a bioprosthetic tricuspid valve failure occurring within two months of surgery.

Case: A 53-year-old woman presented with acute dyspnea and orthopnea two months after a 33-mm Mitris Resilia tricuspid valve replacement for severe tricuspid regurgitation. Her history included mild aortic insufficiency and non-obstructive coronary artery disease. Transthoracic echocardiography revealed a large pericardial effusion with tamponade physiology, necessitating urgent pericardiocentesis. Transesophageal echocardiography demonstrated early SVD of the bioprosthetic valve, with poor leaflet coaptation, a central coaptation gap, and restricted anterior leaflet mobility. Extensive evaluation excluded infectious and autoimmune etiologies: blood cultures, inflammatory markers, viral serologies, thyroid function, and pericardial fluid cytology were unremarkable. Despite pericardial drainage, right atrial pressures remained elevated (mean 19 mmHg) on repeat right heart catheterization. Following a comprehensive heart team evaluation, a 29-mm Edwards Sapien valve was deployed via right internal jugular venous access within the failing surgical valve under fluoroscopic and echocardiographic guidance. Intraprocedural TEE demonstrated immediate reduction of tricuspid regurgitation severity to trace with a mean gradient of 1 mmHg. The patient had an uncomplicated recovery and was discharged the following day.

Conclusion: This case represents one of the earliest reported tricuspid bioprosthetic valve failures requiring intervention within two months of implantation. The exact mechanism of SVD remains unclear; proposed theories include non-calcific mechanisms such as early mechanical leaflet fatigue, material or manufacturing defects, or technical factors related to surgical implantation. The comprehensive negative workup supports intrinsic valve material failure rather than infectious or inflammatory processes. The successful transcatheter ViV approach demonstrates excellent technical feasibility with immediate hemodynamic improvement, confirming its role as a viable alternative to high-risk redo surgery in early valve failure.